Merck KGaA bets on RNAi with $1.3B Silence buyout
divesiranPositive
AI Analysis
Summary
Merck KGaA is acquiring Silence Therapeutics for $1.3 billion, adding an RNAi blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Merck KGaA to acquire Silence Therapeutics for approximately $1.3 billion, gaining an RNAi-based blood disorder medicine that passed a Phase 2 test and could compete with a Takeda drug.
Importance:8/10
Sentiment:
0.60
acquisitionRNAihematologyblood disorderPhase 2M&A
Read the original article
Published by BioPharma Dive on October 19, 2026 1:59 PM